COPD Real-World Evidence Video 1: Relevance of Real-World Data

• Identify limitations of randomized controlled trials in generalizability, duration, and practical feasibility
• Explain how real-world evidence can complement clinical trial findings by reflecting heterogeneous patients and assessing patient-relevant outcomes in routine clinical practice
• Describe how real-world data may help characterize type 2 inflammation and support more personalized treatment in COPD

Real-world evidence can complement clinical trial findings by reflecting the heterogeneous patient populations seen in routine clinical practice. In video 1 of this three-part series, hear Dr. Mustafa Abdo discuss its relevance in COPD with underlying type 2 inflammation. Learn about the outcomes it can capture, including symptoms, quality of life, and lung function, and how repeated eosinophil measurements and treatment responses may help characterize type 2 inflammation and support more personalized treatment.